Editorials
Long-term assessment of fying doctors and their patients as pres ptions drug safety and efficacy for a particular drug pass thrC4h th rescription Pricing Authority. Re iptions are The safety and efficacy of a drug cannot photocopied and copies sent in confidence to the accurately be assessed from short-term clinical Drug Surveillance Research Unit in Southtrials in tens or hundreds of patients. The lesson ampton. Each 'test' drug under investigation is of the last decade with practolol, clofibrate, matched with a 'control' drug which is chemically benoxaprofen, indomethacin and the oral contra-or pharmacologically similar and already ceptive, to mention only some of the more marketed for the same indications. Similar important, must be that long-term post-numbers of patients receiving each drug are marketing studies involving thousands of patients selected and a simple questionnaire is sent to their should become an essential part of the routine general practitioners requesting information on assessment of new drugs, and indeed, as the age, new diagnoses or events that have come to recent 'Osmosin episode' illustrated, of new the doctor's attention, and reasons for any formulations of some older drugs. The present referral to a consultant or admission to hospital. situation, however, is far from satisfactory. In Inman (1981b) believes that this system would spite of our recent experience over the past have identified the practolol syndrome at a much decade, relatively few drugs have been released by earlier stage because the number of diagnoses of the Committee on Safety of Medicines (CSM) psoriasis, or referrals to dermatologists, and of subject to the restriction of 'obligatory feedback eye symptoms, or referrals to ophthalmologists, of information gathered from [their] large scale would have greatly exceeded the number linked usage' (Griffin 1981) . These have included with its control drug propranolol. ketamine, dantrolene sodium, sodium valproate
The Drug Surveillance Reseach Unit has and buprenorphine, but apparently not such recently published the first of a proposed series of major innovations as histamine-2 receptor antag-newsletters through which general practitioners onists, calcium antagonists and dopamine will be informed of the results of their collareceptor agonists, new non-steroidal anti-inflam-borative activities (Inman 1983) . It deals with six matory drjFs, and new formulations of drugs PEM studies conducted since January 1982 on with kno adverse effects such as Osmosin. benoxaprofen, fenbufen, erythromycin, raniti-The rst productive system to date for dine, emepronium bromide and zomepirac. The identifyinwg important drug adverse effects has results of most of these studies have already been been that using Yellow Cardsreply-paid cards reported in the medical journals, but in his on which doctors and dentists are encouraged to newsletter Inman draws attention to some of the report4ny suggested adverse drug reactions to unforeseen problems that arose. For example, a the Committee on Safety of Medicines. Although rail strike delayed the distribution of some the rate of reporting has been low, this system important forms to doctors in distant parts of the drew attention to oral-contraceptive-related country, illustrating the dependence of the thromboembolism, hepatitis and methyldopa, scheme on prompt and efficient postal services. In jaundice and halothane, extrapyramidal effects the case of benoxaprofen (Opren), its promotion and metoclopramide, liver damage and ibufenac. achieved a prescription rate greatly in excess of The Yellow Card system did not, however, draw that predicted by the Research Unit. The Unit attention to the harmful effects of practolol which was able to cope, but this example raises the was taken by more than 100000 patients before important question which the CSM must face at its association with the oculomucocutaneous some time, namely whether pharmaceutical syndrome was recognized (Griffin 1981) . In any companies should be obliged to restrict their case, this system cannot calculate the incidence of promotional and marketing activities until the adverse drug reactions, which must depend on a results of such studies are known. A third measure of drug usage as well as the number of problem encountered by Inman and his adverse events.
colleagues was the inability of doctors always to Among several schemes that have been report the cause of death in particular patients prepared to quantify the incidence of adverse because their notes had been returned to the drug reactions, prescription-event monitoring Family Practitioner Committees. This will require (PEM) has taken an early lead in establishing special arrangements to be made with the Office itself as a credible and practical method (Inman of Population Censuses and Surveys, or with the 1981a,b). Basically, the scheme involves identi-Family Practitioner Committees in order to establish the cause of death. Finally, Inman expresses his concern at the way in which the news media have prejudged the issue of safety of drugs beforeadequate information had been obtained in sufficient numbers of patients for a truly balanced view to be placed before the medical community. 'Confidence in drug treatment is being seriously eroded by the activities of the media' says Inman, and it is an opinion that few doctors would dispute.
This first newsletter reports an encouraging start of an enterprise which needs wholehearted support from the government, pharmaceutical industry, prescribing doctor and clinical academic profession. An independent, impartial facility for post-marketing surveillance now exists in the United Kingdom, and the CSM should consider restricting product licences on more new drugs and formulations until the results of PEM studies demonstrate acceptable safety. PEM is relatively cheap compared with most other methods of drug surveillance, and Inman anticipates that it should identify adverse drug reactions which have an incidence of one in 3000 or greater. Important reactions with a lower incidence will probably still depend on Yellow Card reporting to identify them (Inman 1981a) .
What about the assessment of drug efficacy?
There is no alternative to long-term controlled therapeutic trials to determine the true and comparative efficacy of a drug and its place in patient management, and PEM has not been designed to make a major contribution to this. Nevertheless, clues to comparative therapeutic efficacy may appear and prompt further controlled studies. Inman & Rawson (1983) have recently drawn attention to a less-than-expected number of reports of death from myocardial infarction in patients receiving treatment with zomepirac during a PEM study, and have asked whether it exerts a protective effect against cardiovascular death. This question deserves prospective investigation, but, whatever the answer, it illustrates that PEM may well help to identify unexpected therapeutic benefit as well as unwanted effects of drugs.
Paul 1974 , Stagno et al. 1977a .and Stern & Tucker (1973) in England developed data that demonstrated the public health importance of congenital CMV.
Most observers are now willing to attribute to CMV the title of most common infectious cause of brain damage, with a rate of about 0.1 to 0.3 of all infants born in the US or the UK. Meanwhile, since the early 1960s, the importance of CMV disease has become obvious in renal, bone marrow and cardiac transplant patients. Moreover, transmission of CMV by blood transfusion for surgery or for replenishment of falling haemoglobins in premature infants has been identified as a significant cause of morbidity and mortality. Finally, it is now appreciated that CMV is often transmitted sexually, and that this venereal infection can express itself in a variety of ways: as part of the AIDS syndrome in homosexual men, as cervical infection in women, as acquired neonatal infection in infants born to those women and as infection of the semen in both heterosexual and homosexual men.
In addition to exogenous transmission, studies of transplant CMV infections have also shown that endogenous virus can reactivate in the face of pre-existing immunity, when that immunity is tampered with. A similar process explains the observations that seropositive mothers become cervical excretors late in pregnancy and that fetal infection may take place in their infants.
It needs no sophistication to realize that an infection transmitted in so many different ways, with the capacity to cause disease both during primary infection and by reactivation, would pose novel and difficult problems for the development of prevention. Nevertheless, there are promising developments taking place in the categories of live vaccine, killed vaccine, passive antibody, and prophylactic antivirals. These developments were reviewed at two recent meetings, one held at Philadelphia in April 1983 (Plotkin et al. 1984a , and the other held at the Royal Society of Medicine in May 1983 . Harold Stern (1984 , who first attempted live CMV virus vaccination, presented follow-up data 'Based on paper read to Section of Epidemiology Community Medicine, 25 May 1983 0141-0768/84/020094-02/$01.00/0
